Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
(2022)
Journal Article
Bishton, M. J., Salles, G., Golfier, C., Knauf, W., Bocchia, M., Turner, D., Slama, B., Harchowal, J., Marshall, S., Bosi, A., Lleonart, J. J. B., Welslau, M., Kim, S., Lee, Y. N., Zinzani, P. L., & Laribi, K. (2023). Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe. eJHaem, 4(1), 45-54. https://doi.org/10.1002/jha2.593
The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBC... Read More about Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe.